Skip to main content
OpenTrials
Completed

NCT Number: NCT02557477

Omega 3/6 Fatty Acids for Reading in Children

The primary objective was to assess whether supplementation of Omega 3/6 fatty acids improves mainstream schoolchildren's reading ability. The secondary objective was to assess whether Omega 3/6 improves cognitive functions such as attention, memory, learning, language/communication, problem solving and social ability.This was a 3-month randomised, double-blind, placebo-controlled study followed by one-way crossover (placebo to active treatment) for an additional 3 months. Mainstream schoolchildren aged 9-10 years were initially randomised to receive three Omega 3/6 capsules twice daily or identical placebo. All outcome measures were assessed at baseline, 3 months and 6 months. The primary outcome measure was the LOGOS test, a comprehensive test battery for evaluating reading abilities. Secondary outcome measures were the parent-rated Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale-IV, 5-15 scale (domains of learning, memory, language/communication and problem solving); Social and Communication Disorders Checklist (to evaluate social ability)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

9 year–10 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

This was a 3-month randomized, double-blind, placebo-controlled study (Period 1) followed by one-way crossover (placebo to active treatment) for an additional 3 months (Period 2). Participants were randomized to receive three Omega 3/6 capsules twice daily (corresponding to a daily dose of 558 mg EPA, 174 mg DHA, and 60 mg gamma-linolenic acid) or identical placebo capsules (palm oil). All daily doses were taken at home supervised by the parents. All outcome measures were assessed at baseline and at the 3- and 6-month follow-up visits. The participants were mainstream schoolchildren in the 3rd school year (aged 9-10 years). Exclusion criteria were continuous supplementation of Omega-3 fatty acids for periods longer than 1 month during the previous year, significant medical conditions (e.g. diabetes, epilepsy), intellectual disability, attention-deficit hyperactivity disorder (ADHD) diagnosis, psychoactive medication, or substance use.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • mainstream schoolchildren in the 3rd school year (aged 9-10 years).

Exclusion criteria

  • continuous supplementation of Omega-3 fatty acids for periods longer than 1 month during the previous year
  • significant medical conditions (e.g. diabetes, epilepsy)
  • intellectual disability
  • attention-deficit hyperactivity disorder (ADHD) diagnosis, psychoactive medication, or substance use.

Treatment and study plan

Omega 3/6 fatty acids

Dietary Supplement

Three Omega 3/6 capsules twice daily

Placebo

Dietary Supplement

Three placebo capsules twice daily

Primary outcomes

  1. Change in reading ability

    Time frame: 0, 3 and 6 months

    LOGOS test: Computerized test of several functions implicated in reading ability

Secondary outcomes

  1. Change in ADHD symptom severity

    Time frame: 0, 3 and 6 months

    ADHD-Rating Scale IV: Parent-rated questionnaire measuring the DSM-IV ADHD symptom criteria

  2. Change in learning ability

    Time frame: 0,3 and 6 months

    FTF scale: Parent-rated questionnaire, domain measuring problem scores in learning ability

  3. Change in memory ability

    Time frame: 0, 3 and 6 months

    FTF scale: Parent-rated questionnaire, domain measuring problem scores in memory ability

  4. Change in language/communication ability

    Time frame: 0,3 and 6 months

    FTF scale: Parent-rated questionnaire, domain measuring problem scores in language/communication ability

  5. Change in problem solving ability

    Time frame: 0,3 and 6 months

    FTF scale: Parent-rated questionnaire, domain measuring problem scores in problem solving ability

  6. Change in social ability

    Time frame: 0,3 and 6 months

    Social and Communication Disorders Checklist (SCDC): Parent-rated checklist measuring social ability

Sponsors and collaborators

Lead sponsor

Göteborg University

Other

Collaborators

  • Vifor Pharma

Registry information

Official study title

Omega 3/6 Fatty Acids for Reading in Children: A Randomised, Double-blind, Placebo-controlled Trial in 9-year-old Mainstream Schoolchildren in Sweden

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Sep 23, 2015
Registry last updated
Dec 27, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.